Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Guo, Fengjie ^a,b,c,d   Li, Yalin ^a,b,c   Wang, Jiajia ^a,b,c   Li, Yandong ^a,b,c   Li, Yuehui ^a,b,c   Li, Guancheng ^a,b,c  

^a Central South University   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; HYPOCALCIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; STANNIOCALCIN 1; THAPSIGARGIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MIGRATION INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; UTERINE CERVIX CANCER;

AGED; ANIMALS; CELL PROLIFERATION; EIF-2 KINASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NF-KAPPA B; PROMOTER REGIONS, GENETIC; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 84873873775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053989     Document Type: Article

References (33)

1. Jiang WQ, Chang AC, Satoh M, Furuichi Y, Tam PP, et al. (2000) The distribution of stanniocalcin 1 protein in fetal mouse tissues suggests a role in bone and muscle development. J Endocrinol 165: 457-466.
2. Yoshiko Y, Aubin JE, (2004) Stanniocalcin 1 as a pleiotropic factor in mammals. Peptides 25: 1663-1669.
3. Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL, (1996) Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 93: 1792-1796.
4. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, et al. (2010) Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812-827.
5. Law AY, Yeung BH, Ching L, Wong CK, (2011) Sp1 is a transcription repressor to stanniocalcin-1 expression in TSA-treated human colon cancer cells, HT29. J Cell Biochem 112: 2089-2096.
6. Wu S, Yoshiko Y, De Luca F, (2006) Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J Biol Chem 281: 5120-5127.
7. Varghese R, Gagliardi AD, Bialek PE, Yee SP, Wagner GF, et al. (2002) Overexpression of human stanniocalcin affects growth and reproduction in transgenic mice. Endocrinology 143: 868-876.
8. Hasilo CP, McCudden CR, Gillespie JR, James KA, Hirvi ER, et al. (2005) Nuclear targeting of stanniocalcin to mammary gland alveolar cells during pregnancy and lactation. Am J Phsiol Endoerinol Metab 289: 634-642.
9. Filvaroff EH, Guillet S, Zlot C, Bao M, Ingle G, et al. (2002) Stanniocalcin 1 alter smuscle and bone structure and function in transgenic mice. Endocrinology 143: 3681-3690.
10. Zaidi D, James KA, Wagner GF, (2006) Passive immunization of lactating mice with stanniocalcin-1 antiserum reduces mammary gland development, milk fat content, and postnatal pup growth. Am J Physiol Endocrinol Metab 291: E974-981.
11. Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, et al. (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112: 241-247.
12. McCudde CR, Majewski A, Chakrabarti S, Wagner GF, (2004) Co-localizaztion of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol Cell Endocrinol 213: 167-172.
13. Fujiwara Y, Sugita Y, Nakamori S, Miyamoto A, Shiozaki K, et al. (2000) Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol 16: 799-804.
14. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, et al. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137.
15. Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, et al. (2008) Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 8: 187.
16. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, et al. (2002) Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161: 249-256.
17. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, et al. (2000) Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 60: 6744-6749.
18. Tohmiya Y, Koide Y, Fujimaki S, Harigae H, Funato T, et al. (2004) Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia. Tohoku J Exp Med 204: 125-133.
19. Tamura S, Oshima T, Yoshihara K, Kanazawa A, Yamada T, et al. (2011) Clinical significance of STC1 gene expression in patients with colorectal cancer. Anticancer Res 31: 325-329.
20. Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, et al. (2002) In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics 10: 13-20.
21. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, et al. (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93: 1337-1343.
22. Law AY, Lai KP, Lui WC, Wan HT, Wong CK, (2008) Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation. Exp Cell Res 314: 2975-2984.
23. del Campo JM, Prat A, Gil-Moreno A, Pérez J, Parera M, (2008) Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110: S72-76.
24. Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, et al. (2009) A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 9: 276-294.
25. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, et al. (2008) Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68: 9323-9330.
26. Diaz-Padilla I, Duran I, Clarke BA, Oza AM, (2012) Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 38: 767-775.
27. Fukasawa M, Tsuchiya T, Takayama E, Shinomiya N, Uyeda K, et al. (2004) Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. J Biochem. 136: 273-277.
28. Thompson JS, Asmis R, Tapp AA, Nelson B, Chu Y,et al. (. 2010) Pyrrolidine dithiocarbamate (PDTC) blocks apoptosis and promotes ionizing radiation-induced necrosis of freshly-isolated normal mouse spleen cells. Apoptosis 15: 705-714.
29. Chang AC, Jellinek DA, Reddel RR, (2003) Mammalian stanniocalcins and cancer. Endocr Relat Cancer 10: 359-373.
30. Law AY, Ching LY, Lai KP, Wong CK, (2010) Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol 314: 118-127.
31. Chen C, Jamaluddin MS, Yan S, Sheikh-Hamad D, Yao Q, (2008) Human stanniocalcin-1 blocks TNF-alpha-induced monolayer permeability in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 28: 906-912.
32. Guo F, Li Y, Liu Y, Wang J, Li G, (2010) ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. Oncol Rep 23: 1449-1455.
33. Li X, Shen L, Zhang J, Su J, Shen L, et al. (2007) Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res 67: 8716-8724.